This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A straightforward take on whether SP 500 or balanced funds fit better for retirement, covering growth potential, risk, and suitability.
25,481 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
The U.S. SEC has ended its enforcement action against ConsenSys over MetaMask Swaps and Staking, with no penalties an...
Perplexity’s decision to base its AI tooling on Nvidia’s Vera CPUs over AMD’s x86 chips signals a major shift in the ...
Christopher Nolan’s The Odyssey opened to $264 million worldwide, surpassing a $250 million budget and signaling how ...
Oil hovers near $70 a barrel as U.S.-Iran tensions flare, signaling a risk premium for energy and a wait-and-see stan...
Argentina presses ahead with sweeping reforms, betting on privatizations and tighter budgets. Investors are turning t...
KORU, the 3X South Korea ETF, tumbles about 28% in a single week even as it posted massive prior gains. The selloff u...
AI chatbots offer big benefits for learning and managing crypto, but risks exist. This article explains how most chat...
TransFi has secured $19 million in funding to push its cross-border stablecoin payments platform into multiple region...
Bhutan’s sovereign fund moved 519.7 BTC, worth about $37 million, to Binance, continuing a months‑long sell-off that ...
Silver markets tighten as COMEX inventories shrink and the pricing curve tightens. Traders ask how long the exchange ...
Gold is climbing as central banks snapping gold drives a new bid, with ETF buyers joining sovereign demand. This piec...